Allostery Investments LP Arcellx, Inc. Transaction History
Allostery Investments LP
- $69.3 Billion
- Q1 2025
A detailed history of Allostery Investments LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Allostery Investments LP holds 44,000 shares of ACLX stock, worth $2.73 Million. This represents 4.16% of its overall portfolio holdings.
Number of Shares
44,000
Previous 35,000
25.71%
Holding current value
$2.73 Million
Previous $2.68 Billion
7.53%
% of portfolio
4.16%
Previous 2.8%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
214Shares Held
48.8MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$279 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$247 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$232 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$218 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$188 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.72B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...